Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer

Tosca Holtrop; Kevin Budding; Arianne M Brandsma; Jeanette H W Leusen

doi:10.1093/immadv/ltac011

Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer

Tosca Holtrop
, Kevin Budding
, Arianne M Brandsma
, Jeanette H W Leusen

Research output: Contribution to journal › Review article › peer-review

5 Downloads (Pure)

Abstract

ADCC/ADCP: Antibody-dependent cellular cytotoxicity/phagocytosis; AIA: Antigen-induced arthritis; ATG: Anti-thymocyte globulin; bsAbs: Bispecific antibodies; CDC: Complement-dependent cytotoxicity; CIA: Collagen-induced arthritis; CY: Cytoplasmic; DRG: Dorsal root ganglion; EC: Extracellular domain; Fab: Antigen-binding fragment; FcγR: Fc gamma receptor; G-CSF: Granulocyte colony-stimulating factor; IC: Immune complex; INF-y: Interferon gamma; ITAM/ITIM: Immunoreceptor tyrosine-based activation/inhibition motif; ITP: Immune Thrombocytopenic Purpura; IVIg: Intravenous immunoglobulin; LN: Lupus nephritis; mAb: Monoclonal antibody; MCP-1: Monocyte chemoattractant protein 1; NK: Natural killer cell; PMN: Polymorphonuclear; PP1: Protein phosphatase 1; RA: Rheumatoid Arthritis; SLE: Systemic lupus erythematosus; TNF-α: Tumor necrosis factor alpha.

Original language	English
Article number	ltac011
Journal	Immunotherapy Advances
Volume	2
Issue number	1
DOIs	https://doi.org/10.1093/immadv/ltac011
Publication status	Published - 2022

Keywords

CD64
autoimmunity
cancer
inside-out signaling
neuropathy
therapeutic antibodies

Access to Document

10.1093/immadv/ltac011Licence: CC BY-NC

ltac011Final published version, 11.6 MBLicence: CC BY-NC

Cite this

@article{009bfb3935fd4f44a948a99bc985495d,

title = "Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer",

abstract = "ADCC/ADCP: Antibody-dependent cellular cytotoxicity/phagocytosis; AIA: Antigen-induced arthritis; ATG: Anti-thymocyte globulin; bsAbs: Bispecific antibodies; CDC: Complement-dependent cytotoxicity; CIA: Collagen-induced arthritis; CY: Cytoplasmic; DRG: Dorsal root ganglion; EC: Extracellular domain; Fab: Antigen-binding fragment; FcγR: Fc gamma receptor; G-CSF: Granulocyte colony-stimulating factor; IC: Immune complex; INF-y: Interferon gamma; ITAM/ITIM: Immunoreceptor tyrosine-based activation/inhibition motif; ITP: Immune Thrombocytopenic Purpura; IVIg: Intravenous immunoglobulin; LN: Lupus nephritis; mAb: Monoclonal antibody; MCP-1: Monocyte chemoattractant protein 1; NK: Natural killer cell; PMN: Polymorphonuclear; PP1: Protein phosphatase 1; RA: Rheumatoid Arthritis; SLE: Systemic lupus erythematosus; TNF-α: Tumor necrosis factor alpha.",

keywords = "CD64, autoimmunity, cancer, inside-out signaling, neuropathy, therapeutic antibodies",

author = "Tosca Holtrop and Kevin Budding and Brandsma, \{Arianne M\} and Leusen, \{Jeanette H W\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

doi = "10.1093/immadv/ltac011",

language = "English",

volume = "2",

journal = "Immunotherapy Advances",

issn = "2732-4303",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer

AU - Holtrop, Tosca

AU - Budding, Kevin

AU - Brandsma, Arianne M

AU - Leusen, Jeanette H W

N1 - Publisher Copyright: © The Author(s) 2022.

PY - 2022

Y1 - 2022

N2 - ADCC/ADCP: Antibody-dependent cellular cytotoxicity/phagocytosis; AIA: Antigen-induced arthritis; ATG: Anti-thymocyte globulin; bsAbs: Bispecific antibodies; CDC: Complement-dependent cytotoxicity; CIA: Collagen-induced arthritis; CY: Cytoplasmic; DRG: Dorsal root ganglion; EC: Extracellular domain; Fab: Antigen-binding fragment; FcγR: Fc gamma receptor; G-CSF: Granulocyte colony-stimulating factor; IC: Immune complex; INF-y: Interferon gamma; ITAM/ITIM: Immunoreceptor tyrosine-based activation/inhibition motif; ITP: Immune Thrombocytopenic Purpura; IVIg: Intravenous immunoglobulin; LN: Lupus nephritis; mAb: Monoclonal antibody; MCP-1: Monocyte chemoattractant protein 1; NK: Natural killer cell; PMN: Polymorphonuclear; PP1: Protein phosphatase 1; RA: Rheumatoid Arthritis; SLE: Systemic lupus erythematosus; TNF-α: Tumor necrosis factor alpha.

AB - ADCC/ADCP: Antibody-dependent cellular cytotoxicity/phagocytosis; AIA: Antigen-induced arthritis; ATG: Anti-thymocyte globulin; bsAbs: Bispecific antibodies; CDC: Complement-dependent cytotoxicity; CIA: Collagen-induced arthritis; CY: Cytoplasmic; DRG: Dorsal root ganglion; EC: Extracellular domain; Fab: Antigen-binding fragment; FcγR: Fc gamma receptor; G-CSF: Granulocyte colony-stimulating factor; IC: Immune complex; INF-y: Interferon gamma; ITAM/ITIM: Immunoreceptor tyrosine-based activation/inhibition motif; ITP: Immune Thrombocytopenic Purpura; IVIg: Intravenous immunoglobulin; LN: Lupus nephritis; mAb: Monoclonal antibody; MCP-1: Monocyte chemoattractant protein 1; NK: Natural killer cell; PMN: Polymorphonuclear; PP1: Protein phosphatase 1; RA: Rheumatoid Arthritis; SLE: Systemic lupus erythematosus; TNF-α: Tumor necrosis factor alpha.

KW - CD64

KW - autoimmunity

KW - cancer

KW - inside-out signaling

KW - neuropathy

KW - therapeutic antibodies

UR - https://www.scopus.com/pages/publications/85152685934

U2 - 10.1093/immadv/ltac011

DO - 10.1093/immadv/ltac011

M3 - Review article

C2 - 36284837

SN - 2732-4303

VL - 2

JO - Immunotherapy Advances

JF - Immunotherapy Advances

IS - 1

M1 - ltac011

ER -

Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this